Skip to content
Screener

Xencor XNCR Shares (Diluted)

Shares (Diluted) at other companies

Amgen logo
AmgenAMGN
544M+0.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
106M-2.4%
Janux Therapeutics logo
Janux TherapeuticsJANX
62.9M+1.7%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
305.6M+2.4%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
28.7M-6.4%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
55.4M+86.4%

Other financials

Income statement

See full
Revenue$51.2M+17.5%
Operating income-$37.1M-11.7%
Net income-$21.7M+29.5%
EPS (diluted)-$0.29+29.3%

Balance sheet

See full
Cash & equivalents$44.7M+0.5%
Total debt$170.1M-20.1%
Total equity$503.2M-18.9%
Total assets$725.0M-17.6%

Cash flow

See full
Operating cash flow-$55.7M-53.0%
CapEx$538.0K+40.5%
Free cash flow-$56.2M-52.9%

Valuation

See full
Market cap$1.55B+210%
Enterprise value$1.67B+150%
P/S14.7×+11.3×

Profitability

See full
Operating margin-205.8%-2,501pp
Net margin-155.6%+78.8pp
FCF margin-198.4%-1,485pp

Returns & leverage

See full
Return on equity-29.1%+0.2pp
Debt / equity0.3×0.0×
Current ratio6.4×+1.1×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Xencor’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:02 PM EDT
Fiscal quarter
Q4 FY2028
Calendar quarter
Q4 2028
Accession
0001326732-26-000056
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Numerator:
Net loss attributable to Xencor, Inc.$(21,729)$(30,825)$(150,645)$(79,243)
Denominator:
Weighted-average basic shares outstanding75,85974,27975,55573,975
Effect of dilutive securities
Weighted-average diluted shares outstanding75,85974,27975,55573,975
Basic and diluted net loss per share$(0.29)$(0.41)$(1.99)$(1.07)

Item 1. Financial Statements

FAQ

What is Xencor's shares (diluted)?
Xencor (XNCR) reported shares (diluted) of 75.9M in Q2 2026.
How has Xencor's shares (diluted) changed year-over-year?
Xencor's shares (diluted) increased by 2.1% year-over-year, from 74.3M to 75.9M.
What is the long-term trend for Xencor's shares (diluted)?
Over 4 years (2021 to 2025), Xencor's shares (diluted) has grown at a 5.7% compound annual growth rate (CAGR), from 237.2M to 296.6M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Xencor's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude